Barclays analyst Matthew Bouley maintains GMS (NYSE:GMS) with a Equal-Weight and raises the price target from $60 to $67.
Oppenheimer Initiates Coverage On Fulcrum Therapeutics with Outperform Rating, Announces Price Target of $33
Oppenheimer analyst Matthew Biegler initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform rating and announces Price Target of $33.